Blended Nanostructured Degradable Mesh with Endometrial Mesenchymal Stem Cells Promotes Tissue Integration and Anti-Inflammatory Response in Vivo for Pelvic Floor Application

Shayanti Mukherjee, Saeedeh Darzi, Anna Rosamilia, Vinod Kadam, Yen Truong

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The current urogynecological clinical meshes trigger unfavorable foreign body response which leads to graft failure in the long term. To overcome the present challenge, we applied a tissue engineering strategy using endometrial SUSD2+ mesenchymal stem cells (eMSCs) with high regenerative properties. This study delves deeper into foreign body response to SUSD2+ eMSC based degradable PLACL/gelatin nanofiber meshes using a mouse model targeted at understanding immunomodulation and mesh integration in the long term. Delivery of cells with nanofiber mesh provides a unique topography that enables entrapment of therapeutic cells for up to 6 weeks that promotes substantial cellular infiltration of host anti-inflammatory macrophages. As a result, degradation rate and tissue integration are highly impacted by eMSCs, revealing an unexpected level of implant integration over 6 weeks in vivo. From a clinical perspective, such immunomodulation may aid in overcoming the current challenges and provide an alternative to an unmet women's urogynecological health need.

Original languageEnglish
Pages (from-to)454-468
Number of pages15
JournalBiomacromolecules
Volume20
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Cite this

@article{f1f77e04b67041fd8ce289500b831b51,
title = "Blended Nanostructured Degradable Mesh with Endometrial Mesenchymal Stem Cells Promotes Tissue Integration and Anti-Inflammatory Response in Vivo for Pelvic Floor Application",
abstract = "The current urogynecological clinical meshes trigger unfavorable foreign body response which leads to graft failure in the long term. To overcome the present challenge, we applied a tissue engineering strategy using endometrial SUSD2+ mesenchymal stem cells (eMSCs) with high regenerative properties. This study delves deeper into foreign body response to SUSD2+ eMSC based degradable PLACL/gelatin nanofiber meshes using a mouse model targeted at understanding immunomodulation and mesh integration in the long term. Delivery of cells with nanofiber mesh provides a unique topography that enables entrapment of therapeutic cells for up to 6 weeks that promotes substantial cellular infiltration of host anti-inflammatory macrophages. As a result, degradation rate and tissue integration are highly impacted by eMSCs, revealing an unexpected level of implant integration over 6 weeks in vivo. From a clinical perspective, such immunomodulation may aid in overcoming the current challenges and provide an alternative to an unmet women's urogynecological health need.",
author = "Shayanti Mukherjee and Saeedeh Darzi and Anna Rosamilia and Vinod Kadam and Yen Truong",
year = "2019",
month = "1",
day = "1",
doi = "10.1021/acs.biomac.8b01661",
language = "English",
volume = "20",
pages = "454--468",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society (ACS)",
number = "1",

}

Blended Nanostructured Degradable Mesh with Endometrial Mesenchymal Stem Cells Promotes Tissue Integration and Anti-Inflammatory Response in Vivo for Pelvic Floor Application. / Mukherjee, Shayanti; Darzi, Saeedeh; Rosamilia, Anna; Kadam, Vinod; Truong, Yen.

In: Biomacromolecules, Vol. 20, No. 1, 01.01.2019, p. 454-468.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Blended Nanostructured Degradable Mesh with Endometrial Mesenchymal Stem Cells Promotes Tissue Integration and Anti-Inflammatory Response in Vivo for Pelvic Floor Application

AU - Mukherjee, Shayanti

AU - Darzi, Saeedeh

AU - Rosamilia, Anna

AU - Kadam, Vinod

AU - Truong, Yen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The current urogynecological clinical meshes trigger unfavorable foreign body response which leads to graft failure in the long term. To overcome the present challenge, we applied a tissue engineering strategy using endometrial SUSD2+ mesenchymal stem cells (eMSCs) with high regenerative properties. This study delves deeper into foreign body response to SUSD2+ eMSC based degradable PLACL/gelatin nanofiber meshes using a mouse model targeted at understanding immunomodulation and mesh integration in the long term. Delivery of cells with nanofiber mesh provides a unique topography that enables entrapment of therapeutic cells for up to 6 weeks that promotes substantial cellular infiltration of host anti-inflammatory macrophages. As a result, degradation rate and tissue integration are highly impacted by eMSCs, revealing an unexpected level of implant integration over 6 weeks in vivo. From a clinical perspective, such immunomodulation may aid in overcoming the current challenges and provide an alternative to an unmet women's urogynecological health need.

AB - The current urogynecological clinical meshes trigger unfavorable foreign body response which leads to graft failure in the long term. To overcome the present challenge, we applied a tissue engineering strategy using endometrial SUSD2+ mesenchymal stem cells (eMSCs) with high regenerative properties. This study delves deeper into foreign body response to SUSD2+ eMSC based degradable PLACL/gelatin nanofiber meshes using a mouse model targeted at understanding immunomodulation and mesh integration in the long term. Delivery of cells with nanofiber mesh provides a unique topography that enables entrapment of therapeutic cells for up to 6 weeks that promotes substantial cellular infiltration of host anti-inflammatory macrophages. As a result, degradation rate and tissue integration are highly impacted by eMSCs, revealing an unexpected level of implant integration over 6 weeks in vivo. From a clinical perspective, such immunomodulation may aid in overcoming the current challenges and provide an alternative to an unmet women's urogynecological health need.

UR - http://www.scopus.com/inward/record.url?scp=85058871820&partnerID=8YFLogxK

U2 - 10.1021/acs.biomac.8b01661

DO - 10.1021/acs.biomac.8b01661

M3 - Article

VL - 20

SP - 454

EP - 468

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 1

ER -